196 related articles for article (PubMed ID: 27120485)
1. Alteration of steric hindrance modulates glutathione resistance and cytotoxicity of three structurally related Ru(II)-p-cymene complexes.
Purkait K; Chatterjee S; Karmakar S; Mukherjee A
Dalton Trans; 2016 May; 45(20):8541-55. PubMed ID: 27120485
[TBL] [Abstract][Full Text] [Related]
2. Ruthenium(ii) p-cymene complexes of a benzimidazole-based ligand capable of VEGFR2 inhibition: hydrolysis, reactivity and cytotoxicity studies.
Bhattacharyya S; Purkait K; Mukherjee A
Dalton Trans; 2017 Jul; 46(26):8539-8554. PubMed ID: 28638907
[TBL] [Abstract][Full Text] [Related]
3. A hypoxia efficient imidazole-based Ru(II) arene anticancer agent resistant to deactivation by glutathione.
Purkait K; Karmakar S; Bhattacharyya S; Chatterjee S; Dey SK; Mukherjee A
Dalton Trans; 2015 Apr; 44(13):5969-73. PubMed ID: 25742181
[TBL] [Abstract][Full Text] [Related]
4. Half-Sandwich Iridium(III) and Ruthenium(II) Complexes Containing P^P-Chelating Ligands: A New Class of Potent Anticancer Agents with Unusual Redox Features.
Li J; Tian M; Tian Z; Zhang S; Yan C; Shao C; Liu Z
Inorg Chem; 2018 Feb; 57(4):1705-1716. PubMed ID: 29400963
[TBL] [Abstract][Full Text] [Related]
5. Screening organometallic binuclear thiosemicarbazone ruthenium complexes as potential anti-tumour agents: cytotoxic activity and human serum albumin binding mechanism.
Demoro B; de Almeida RF; Marques F; Matos CP; Otero L; Costa Pessoa J; Santos I; Rodríguez A; Moreno V; Lorenzo J; Gambino D; Tomaz AI
Dalton Trans; 2013 May; 42(19):7131-46. PubMed ID: 23519281
[TBL] [Abstract][Full Text] [Related]
6. Half-sandwich Ru(η
Huang YC; Haribabu J; Chien CM; Sabapathi G; Chou CK; Karvembu R; Venuvanalingam P; Ching WM; Tsai ML; Hsu SCN
J Inorg Biochem; 2019 May; 194():74-84. PubMed ID: 30831392
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxic Ru
Sarkar A; Acharya S; Khushvant K; Purkait K; Mukherjee A
Dalton Trans; 2019 May; 48(21):7187-7197. PubMed ID: 30601545
[TBL] [Abstract][Full Text] [Related]
8. Bipyrimidine ruthenium(II) arene complexes: structure, reactivity and cytotoxicity.
Betanzos-Lara S; Novakova O; Deeth RJ; Pizarro AM; Clarkson GJ; Liskova B; Brabec V; Sadler PJ; Habtemariam A
J Biol Inorg Chem; 2012 Oct; 17(7):1033-51. PubMed ID: 22791215
[TBL] [Abstract][Full Text] [Related]
9. Combining [arene-Ru] with azocarboxamide to generate a complex with cytotoxic properties.
Sommer MG; Kureljak P; Urankar D; Schweinfurth D; Stojanović N; Bubrin M; Gazvoda M; Osmak M; Sarkar B; Košmrlj J
Chemistry; 2014 Dec; 20(52):17296-9. PubMed ID: 25376425
[TBL] [Abstract][Full Text] [Related]
10. Development of novel ruthenium(II)-arene complexes displaying potent anticancer effects in glioblastoma cells.
Kumar P; Mondal I; Kulshreshtha R; Patra AK
Dalton Trans; 2020 Oct; 49(38):13294-13310. PubMed ID: 32936191
[TBL] [Abstract][Full Text] [Related]
11. Effect of
Mukherjee A; Acharya S; Purkait K; Chakraborty K; Bhattacharjee A; Mukherjee A
Inorg Chem; 2020 May; 59(9):6581-6594. PubMed ID: 32295347
[TBL] [Abstract][Full Text] [Related]
12. 3-Hydroxyflavones vs. 3-hydroxyquinolinones: structure-activity relationships and stability studies on Ru(II)(arene) anticancer complexes with biologically active ligands.
Kurzwernhart A; Kandioller W; Enyedy ÉA; Novak M; Jakupec MA; Keppler BK; Hartinger CG
Dalton Trans; 2013 May; 42(17):6193-202. PubMed ID: 23168616
[TBL] [Abstract][Full Text] [Related]
13. New ruthenium(II) arene complexes of anthracenyl-appended diazacycloalkanes: effect of ligand intercalation and hydrophobicity on DNA and protein binding and cleavage and cytotoxicity.
Ganeshpandian M; Loganathan R; Suresh E; Riyasdeen A; Akbarsha MA; Palaniandavar M
Dalton Trans; 2014 Jan; 43(3):1203-19. PubMed ID: 24177707
[TBL] [Abstract][Full Text] [Related]
14. Ruthenium(II) complexes: DNA-binding, cytotoxicity, apoptosis, cellular localization, cell cycle arrest, reactive oxygen species, mitochondrial membrane potential and western blot analysis.
Li W; Jiang GB; Yao JH; Wang XZ; Wang J; Han BJ; Xie YY; Lin GJ; Huang HL; Liu YJ
J Photochem Photobiol B; 2014 Nov; 140():94-104. PubMed ID: 25108205
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, characterization, interactions with 9-MeG and cytotoxic activity of heterobimetallic Ru
Tsolis T; Nikolaou N; Ypsilantis K; Kougioumtzi A; Kordias D; Magklara A; Garoufis A
J Inorg Biochem; 2021 Jun; 219():111435. PubMed ID: 33819801
[TBL] [Abstract][Full Text] [Related]
16. Towards targeting anticancer drugs: ruthenium(ii)-arene complexes with biologically active naphthoquinone-derived ligand systems.
Kubanik M; Kandioller W; Kim K; Anderson RF; Klapproth E; Jakupec MA; Roller A; Söhnel T; Keppler BK; Hartinger CG
Dalton Trans; 2016 Aug; 45(33):13091-103. PubMed ID: 27214822
[TBL] [Abstract][Full Text] [Related]
17. Imine-N-Heterocyclic Carbenes as Versatile Ligands in Ruthenium(II) p-Cymene Anticancer Complexes: A Structure-Activity Relationship Study.
Yang Y; Guo L; Tian Z; Liu X; Gong Y; Zheng H; Ge X; Liu Z
Chem Asian J; 2018 Oct; 13(19):2923-2933. PubMed ID: 30101417
[TBL] [Abstract][Full Text] [Related]
18. Novel half-sandwich iridium(iii) imino-pyridyl complexes showing remarkable in vitro anticancer activity.
Li J; Guo L; Tian Z; Tian M; Zhang S; Xu K; Qian Y; Liu Z
Dalton Trans; 2017 Nov; 46(44):15520-15534. PubMed ID: 29090698
[TBL] [Abstract][Full Text] [Related]
19. Derivation of structure-activity relationships from the anticancer properties of ruthenium(II) arene complexes with 2-aryldiazole ligands.
Martínez-Alonso M; Busto N; Jalón FA; Manzano BR; Leal JM; Rodríguez AM; García B; Espino G
Inorg Chem; 2014 Oct; 53(20):11274-88. PubMed ID: 25302401
[TBL] [Abstract][Full Text] [Related]
20. ATP7B Binds Ruthenium(II)
Purkait K; Ruturaj ; Mukherjee A; Gupta A
Inorg Chem; 2019 Nov; 58(22):15659-15670. PubMed ID: 31657924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
